LONDON (Reuters) – Cardiologists and shareholders in GlaxoSmithKline
Britain’s biggest drugmaker hopes its once-daily pill darapladib can prevent heart attacks and strokes by fighting clogged arteries in a completely different way from cholesterol-lowering drugs.
Read more